A Clearinghouse for Information about Blood Clots (DVT/)PE) and Clotting Disorders (thrombophilia) provided as a public service by the University of North Carolina Blood Research Center

Tag: DVT

  • DVT in Young Adults – IVC Abnormalities

    Stephan Moll, MD writes….. When a young person is diagnosed with extensive pelvic DVT or inferior vena cava thrombosis, there may be an underlying and predisposing congenital abnormality of the IVC, such as a congenital absence (agenesis, aplasia) or narrowing (hypoplasia) of the IVC

  • Psychological impact of DVT and PE

    Beth Waldron, Program Director of Clot Connect, writes… The patient diagnosed with VTE (venous thromboembolism) may develop depression and anxiety, particularly if the clot was extensive and life-threatening.  However, evaluation of the care and outcome of patients with VTE is often focused upon the visible short-term effects of a clot, such as:  Has the acute clotting…

  • New ACCP Guidelines – DVT and PE: Highlights and Summary

    Stephan Moll, MD writes…  This month the American College of Chest Physicians (ACCP) published its new (2012) guidelines regarding anticoagulation and management of various thrombotic disorders, replacing the 2008 edition. The details of the new guidelines can be found here

  • Xarelto and DVT – Approved in Europe

    Xarelto (Rivaroxaban) was approved in Europe today (Dec 19th, 2011) for patients with acute DVT. This is good news

  • Another New Blood Thinner FDA Approved : Xarelto (Rivaroxaban)

    Today the FDA approved Xarelto (Rivaroxaban) for irregular heart beat (= atrial fibrillation = a. fib).  The approved dose is 20 mg once daily.  The link to the FDA press release is here.  The Xarelto prescribing information can be found here. Xarelto for Blood Clots in the Veins (DVT and PE)

  • Hip and Knee Replacement – DVT Prevention – New Guideline

    Two main guidelines exist which many physicians go by to decide whether a particular patient should get DVT prophylaxis after hip or knee replacement surgery, what method (compression device, or drug) to use, and for how long to give prophylaxis.  (a) One is the ACCP guideline (American College of Chest Physicians), last published in June 2008 [ref…

  • Yasmin, Yaz and Other Drospirenone Contraceptives: Risk for VTE

    It has long been known that estrogen-containing birth control preparations (pill, patch, ring) increase the risk for DVT and PE (venous thromboembolism = VTE).  This risk is partially due to the estrogen.  However, part of the risk is also due to the type of progestin in these preparations.

  • Nattokinase

    Your patient may inquire whether he/she can take Nattokinase instead of staying on warfarin to prevent future venous thromboembolism; or what you think about the effectiveness of Nattokianse in preventing a first or recurrent DVT or PE.